After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

Pre-existing immunity to seasonal endemic coronaviruses could have profound
consequences for antibody responses to SARS-CoV-2, induced from natural infection or …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

Detailed studies of the broadly neutralizing antibodies (bNAbs) that underlie the best
available examples of the humoral immune response to HIV are providing important …

Beginning in 2009, studies of the humoral responses of HIV‐positive individuals have led to
the identification of scores, if not hundreds, of antibodies that are both broadly reactive and …

Induction of HIV‐1 broadly neutralizing antibodies (bnAbs) to date has only been observed
in the setting of HIV‐1 infection, and then only years after HIV transmission. Thus, the …

The generation of HIV bnAbs may be one of the greatest feats of the human immune system
and our best hope of finally creating an HIV vaccine. The striking amount of somatic …

Some HIV-1–infected patients develop broad and potent HIV-1 neutralizing antibodies
(bNAbs) that when passively transferred to mice or macaques can treat or prevent infection …

Broadly neutralizing antibodies (bnAbs) are potential therapeutic molecules and valuable
tools for studying conserved viral targets for vaccine and drug design. Interestingly, antibody …